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Background. Polyomavirus nephropathy (BKVN) is an important cause of chronic allograft
dysfunction (CAD). Recipient determinants (male sex, white race, and older age), deceased
donation, high-dose immunosuppression, diabetes, delayed graft function (DGF),
cytomegalovirus infection, and acute rejection (AR) are risk factors. Reducing
immunosuppression is the best strategy in BKVN. The objective of our study was to evaluate
CAD progression after therapeutic strategies in BKVN and risk factors for graft loss (GL).
Methods. Retrospective analysis of 23 biopsies, from patients with CAD and histological
evidence of BKVN, conducted over a period of 10 years. Glomerular filtration rate
was <30 mL/min in 16 patients at the time of the BKVN diagnosis.
Results. BKVN was histologically diagnosed in 23 recipients (19 men, 4 women). All pa-
tients were white, with age of 51.2  12.1 years (6 patients, age >60 years), and 22 had a
deceased donor. Diabetes affected 4 patients, DGF occurred in 3, cytomegalovirus infection
in 2, and AR in 15. All patients were medicated with calcineurin inhibitors (CNI) (95.7%
tacrolimus) and corticoids, and 16 also received an antimetabolite. One year after antime-
tabolite reduction/discontinuation and/or CNI reduction/switching and/or antiviral agents,
graft function was decreased in 11 patients, increased/stabilized in 10, and unknown in 2. GL
occurred in 9 patients. Older age (hazard ratio, 1.76; 95% confidence interval, 0.94e3.28) and
DGF (hazard ratio, 2.60; 95% confidence interval, 0.54e12.64) were the main risk factors for
GL. The lower GFR at the time of the BKVN diagnosis was associated with an increased risk
of initiation of dialysis.
Conclusions. GL occurred in 39.1% of patients with BKVN and DGF; older age and
lower GFR at the time of diagnosis were important risk factors. Early diagnosis of BKVN is
essential to prevent GL.*Address correspondence to Joana Silva Costa, Centro Hos-
pitalar e Universitário de CoimbraeHospitais da Universidade de
Coimbra, Serviço de Nefrologia, Praceta Prof. Mota Pinto,
Coimbra 3000-075, Portugal. E-mail: joana.c.s.costa@gmail.comBK VIRUS (BKV) is a non-enveloped DNA virus of thepolyomaviridae family, and 80% to 90% of the general
population is seropositive for BKV [1]. Primary infection
usually occurs in the first decade of life, probably by respi-
ratory or oral transmission, and then becomes latent mainly
in the urinary tract [2]. Under sustained and intensive
immunosuppression, the reactivation of latent BKV can
occur, leading to polyomavirus-associated nephropathy
(BKVN) in 1% to 10% of kidney transplant patients [2],
most frequently in the first 2 years after transplantation [3].
This progressively affects graft function and increases thevier Inc. All rights reserved.
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(GL) [2], more often with BKVN late diagnosis. BKV
incidence has increased since the mid-90s with the use of
new powerful immunosuppressor treatments [4]. Because
effective and safe antiviral therapies are lacking [2,3],0041-1345/17
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Fig 1. BK virus nephropathy in kidney allograft biopsies. (A) Tubular epithelial cells with large, irregular nuclei, nucleoli, basophilic chro-
matin, and vesicular changes; hematoxylin and eosin (HE) stain, magnification 400. (B) Polyomavirus intranuclear inclusions (arrows) in
the tubular epithelial cells; HE stain, magnification 400. (C) Characteristic nuclear staining reaction (antibody directed against the BKV
SV40 T antigen) demonstrated by immunohistochemistry; magnification 400.
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Dowidentification of risk factors and screening for BKV repli-
cation is essential.
Some of the risk factors for BKVN are donor determinants
(HLA mismatches and deceased donation), recipient
determinants (older age, male sex, white race), and modulating
factors after transplantation (acute rejection, delayed graft
function [DGF], steroid exposure, lymphocyte-depleting anti-
body medication, high dose of immunosuppressive medication,
and tacrolimusemycophenolic acid comparedwith cyclosporine-
mycophenolic acid or mTOR inhibitor combinations) [2].
Viremia by polymerase chain reaction (PCR) detection is
the recommended screening test for BKVN. A level superior
to 104 copies/mL is associated with a 93% specificity [2] and
can establish “presumptive BKVN” [2,5]. However, only
histological findings of BKVN (cytopathic tubular epithelial
cell changes, intra-nuclear viral inclusion bodies in tubular
epithelial cells, and immunohistochemistry detection of
monoclonal antibodies directed against BKV SV40 T anti-
gen) in the allograft biopsy allows its definitive diagnosis [2,5].Fig 2. Kaplan-Meier estimate of time to dialysis after BKVN diagnos
end of the study (A) and for the first 20 months after the diagnosis o
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sion, which appears to be the best therapeutic strategy to
delay the progression of CAD. Most studies consider that a
period ofmore than 12weeks of reduced immunosuppression
is required to significantly reduce viral load levels [5]. The
effectiveness of additional strategies such as switching
immunosuppressive medication (eg, calcineurin inhibitors
(CNI) to mTOR inhibitor), with no randomized, controlled
trial recommending one over the other, or use of antiviral
therapy (quinolone or leflunamide), are still not proven [2,3].
The objective of the studywas to evaluateCADprogression
after therapeutic strategies in BKVN and risk factors for GL.METHODS
We retrospectively reviewed 23 kidney allograft biopsies from
patients with CAD, between January 2005 and December 2015. All
patients had histological evidence of BKVN, with intra-nuclear viral
inclusions in the tubular epithelial cells, stained with hematoxylin-is (including 95% CIs), from the time of BKVN diagnosis until the
f BKVN (B).
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Table 1. Individual Characteristics (1)
Id G Age (Years) Donor DGF
Immunosuppression
at Diagnosis Therapeutic Strategy
1 M 56 D No FK þ PDN Quinolone þ antimetabolite reduction/discontinuation þ conversion FK to EVE
2 M 55 D No MY þ FK þ PDN Quinolone þ antimetabolite reduction/discontinuation þ conversion FK to EVE
3 M 63 D No MY þ FK þ PDN Quinolone þ CNI reduction þ antimetabolite reduction/discontinuation
4 F 42 D No FK þ PDN Quinolone þ antimetabolite reduction/discontinuation þ conversion FK to EVE
5 M 53 D No MY þ FK þ PDN antimetabolite reduction/discontinuation þ conversion FK to EVE
6 M 31 D No MY þ FK þ PDN CNI reduction
7 M 25 D Yes MMF þ FK þ PDN CNI reduction þ antimetabolite reduction/discontinuation
8 F 38 D No MMF þ FK þ PDN antimetabolite reduction/discontinuation þ CNI reduction
9 M 65 D No FK þ PDN Quinolone þ CNI reduction þ antimetabolite reduction/discontinuation
10 M 34 D No FK þ PDN conversion FK to EVE
11 M 53 D No FK þ PDN Quinolone þ CNI reduction þ antimetabolite reduction/discontinuation
12 F 48 D No MY þ FK þ PDN Quinolone þ Leflunamide þ antimetabolite reduction/discontinuation þ conversion
FK to EVE
13 M 52 D No MMF þ FK þ PDN Quinolone þ antimetabolite reduction/discontinuation þ conversion FK to CyP
14 F 61 D No MY þ FK þ PDN Quinolone þ antimetabolite reduction/discontinuation þ conversion FK to CyP
15 M 54 L No MY þ FK þ PDN Quinolone þ Leflunamide þ CNI reduction þ antimetabolite reduction/
discontinuation
16 M 47 D No MMF þ CyP þ PDN Leflunamide þ antimetabolite reduction/discontinuation þ conversion CyP to EVE
17 M 46 D Yes MMF þ FK þ PDN Leflunamide þ antimetabolite reduction/discontinuation þ conversion FK to CyP
18 M 48 D No MY þ FK þ PDN Leflunamide þ CNI reduction þ antimetabolite reduction/discontinuation
19 M 44 D No MMF þ FK þ PDN Quinolone þ conversion FK to CyP þ antimetabolite reduction/discontinuation
20 M 66 D No MMF þ FK þ PDN antimetabolite reduction/discontinuation
21 M 74 D Yes FK þ PDN Quinolone þ CNI reduction þ antimetabolite reduction/discontinuation
22 M 56 D No AZA þ FK þ PDN CNI reduction
23 M 66 D No FK þ PDN CNI reduction þ antimetabolite reduction/discontinuation
Abbreviations: AZA, azathioprine; CNI, calcineurin inhibitor; CyP, cyclosporine; D, deceased donor; DGF, delayed graft function; EVE, everolimus; F, female; FK,
tacrolimus; G, gender; L, living donor; M, male; MFA, mycophenolic acid; MMF, mycophenolate mofetil; PDN, prednisone.
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Doweosin, and positive polyomavirus SV40 large T-antigen expression,
by immunohistochemistry (Fig 1). Data regarding transplant
recipient and donor demographics, plasma BKV (viremia) values,
glomerular filtration rate (GFR) and immunosuppressive
medication at the time of the biopsy, BKVN therapeutic strategy
and posterior viremia, and graft function evolution were collected.
At the time of the biopsy, viremia was >104 copies/mL in 13
patients, 104 copies/mL in 5 patients, and not tested in 5 patients;
plasmatic creatinine was 3.3  1.2 mg/dL and GFR (MDRD)
was <30 mL/min in 16 patients. BKV DNA was detected through
the use of a quantitative PCR assay and BKV viremia was defined
positive when there were >104 copies/mL and negative when there
were 104 copies/mL. Date of diagnosis of BKVN was defined as
the date of the first biopsy with positive immunohistochemistry for
BKV.
The statistical analysis was event-driven, being the event of
interest initiation of dialysis. Overall probabilities of not initiating
dialysis were obtained and plotted by use of the Kaplan-Meier
method and compared by means of the log-rank test when appli-
cable. Univariate analysis was performed to identify potential risk
factors, using the Cox proportional hazards model to obtain hazard
ratios (HR). The Fisher exact test was also calculated, when
possible, to assess the individual predictive value of each factor
regardless of the time factor. All statistical analysis were conducted
using R Statistical Software version 3.2.5.
RESULTS
BKVN was histologically diagnosed in 23 kidney
recipients during the 10-year period analyzed, 17.8  33.3
months after transplant. Figure 2 shows that the risk ofnloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hosp
For personal use only. No other uses without permission.GL is higher during the first 12 months after the diagnosis
of BKVN. The individual characteristics of these patients
are shown in Tables 1 and 2. All patients were white,
mean age was 51.2  12.1 years (6 patients were >60 years
of age), and the majority (19 patients) were men. Almost
all patients had a deceased donor (22 patients), and
basiliximab was the most commonly used induction ther-
apy agent (18 patients). At the time of the biopsy, all
patients were medicated with CNI (22 patients with
tacrolimus [FK], 1 patient with cyclosporine [CyP]) and
corticoids, in combination with an antimetabolite in 16
patients (mycophenolic acid in 8 patients, mycophenolate
mofetil in 7 patients, and azathioprine in 1 patient).
Diabetes affected 4 patients: 1 patient had type 2 diabetes
mellitus previous to the transplant and 3 patients were
diagnosed with new-onset diabetes after transplantation.
DGF occurred in 3 patients. There was cytomegalovirus
infection in 1 patient at the time of the biopsy and in 1
patient before the biopsy. Acute rejection (AR) was
diagnosed in 3 patients at the time of BKVN diagnosis
(one with borderline rejection and one with T-celle
mediated rejection type IB, both medicated with methyl-
prednisolone pulse therapy [MTP]; one with acute
antibody-mediated rejection, medicated with immuno-
globulin therapy, plasmapheresis, and rituximab) and in
12 patients before the biopsy (6 patients medicated with
MTP, 3 patients medicated with MTP þ thymoglobulin,
and 3 non-medicated patients).italar e Universitário de Coimbra from ClinicalKey.com by Elsevier on June 08, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.















1 Yes No No 15e29 Yes Decreased Increased No
2 No No No 15e29 Yes Decreased U No
3 Yes No Yes 15e29 Yes U U No
4 No No Yes 15e29 Yes Negative Increased No
5 No D Yes 30e44 No Decreased Stabilized No
6 No No No 45e59 U Negative Yes No
7 No No Yes 30e44 U U Increased No
8 No No Yes 30e44 No Negative Stabilized No
9 No No Yes <15 No Decreased Yes Yes
10 No No Yes 30e44 Yes Decreased Stabilized No
11 No No No 15e29 Yes Negative Increased No
12 No No No 15e29 Yes Increased Stabilized No
13 No No Yes 15e29 No Negative Increased No
14 No PrD No <15 Yes Decreased Yes Yes
15 No No Yes 30e44 Yes Decreased Yes No
16 No No No 30e44 Yes Decreased Yes Yes
17 No No No 15e29 U U Yes Yes
18 No No Yes <15 Yes U Yes Yes
19 No No Yes 15e29 No U Yes Yes
20 Yes No Yes <15 U Decreased Increased No
21 No No Yes <15 Yes Decreased Yes Yes
22 No No Yes 15e29 Yes U Yes Yes
23 Yes No Yes 15e29 U U Yes Yes
Abbreviations: CMV, cytomegalovirus; D, at diagnosis of BKVN; DGF, delayed graft function; GFR, glomerular filtration rate; GL, graft loss; PrD, previous to diagnosis
of BKVN; U, unknown.
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DowAlthoughnot statistically significant,olderage(HR,1.76;95%
confidence interval [CI], 0.94e3.28) and DGF (HR, 2.60; 95%
CI, 0.54e12.64) Cox regression estimates were high (Table 3),
which may denote them as important risk factors for GL.
The lower GFR at the time of the BKVN diagnosis was
associated with an increased risk of initiation of dialysis.Table 3. Risk Factors for
Factor n (N) HR
Age (range, 10 years) NA 1.76 (
Male sex 8 (19)
Deceased donor type 9 (22)
Immunosuppression therapy
FK þ PDN 3 (7) 1.32 (
MY þ FK þ PDN 2 (8) 0.47 (
MMF þ FK þ PDN 2 (6) 0.678 (
MMF þ CyP þ PDN 1 (1) 3.14 (
AZA þ FK þ PDN 1 (1) 10.49 (
Diabetes mellitus 1 (4) 0.64 (
DGF 2 (3) 2.60 (
CMV infection 1 (2) 1.07 (
Acute rejection 6 (15) 1.06 (
Viremia >104 copies/mL at the diagnosis 5 (13) 1.12 (
GFR group at BKVN diagnosis
<15 mL/min 4 (5)
15e29 mL/min 4 (11) 0.35 (
30e44 mL/min 1 (6) 0.12 (
45e59 mL/min 0 (1)
Abbreviations: AZA, azathioprine; CyP, cyclosporine; FK, tacrolimus; MFA, myco
dialysis; N, subjects at risk; NA, not applicable; NE, non-estimable; PDN, prednisone
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approximately one-third less likely of starting dialysis than
patients with GFR <15 mL/min. Kaplan-Meier plots (Fig 3)
also support these findings.
The immunosuppressive medication was reduced in all
patients, and at least one of the following therapeuticInitiation of Dialysis


















phenolic acid; MMF, mycophenolate mofetil; n, subjects who had undergone
; RG, reference group.
italar e Universitário de Coimbra from ClinicalKey.com by Elsevier on June 08, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
Fig 3. Kaplan-Meier estimate of time to dialysis after BKVN diagnosis by GFR baseline group: from the time of BKVN diagnosis until
the end of the study (A) and for the first 20 months after the diagnosis of BKVN (B).
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Dowstrategies was used: antimetabolite reduction/discontinua-
tion in 20 patients, CNI substitution in 11 patients (FK to
everolimus in 6 patients, FK to CyP in 4 patients, and CyP to
everolimus in 1 patient), and CNI reduction in 11 patients.
Antiviral therapy was used in 15 patients (quinolones during
6 months in 10 patients, oral leflunamide in 3 patients, or
both in 2 patients). One year after the initiation of these
therapeutic strategies, viremia was increased in 1 patient,
reduced in 10 patients, negative (104 copies/mL) in 5 pa-
tients, and was not evaluated in 7 patients; allograft function
was increased (total recovery in 1 patient, partial recovery in
5 patients) or stabilized in 10 patients (43.5%), decreased in
11 patients, and unknown in 2 patients. GL occurred in 9
patients (39.1%), 8 of them with GFR <30 mL/min (mean
GFR of 17.6 mL/min) at the time of biopsy. Of these pa-
tients, 4 were >60 years of age, 8 were men, 1 was diabetic, 1
had CMV infection, 6 had previous AR (mostly medicated
with corticoid þ thymoglobulin), and 5 had viremia >104
copies/mL at diagnosis (Tables 1 and 2). The mean post-
diagnosis follow-up of the patients was 21.1  21.6 months.DISCUSSION
In our study, we reviewed renal allograft biopsies that were
performed in 23 patients in the setting of CAD and estab-
lished the diagnosis of BKVN. These patients were white and
mainly of male sex, had a deceased donor, and had AR, well-
known risk factors for BKVN. On the other hand, this study
revealed that the main risk factors associated with GL were
older age and DGF. Although high values of HR have also
been seen for MMF þ CyP þ PDN and AZA þ FK þ PDN
medication at the time of diagnosis of BKVN (Table 3), this
finding should be interpreted carefully because only onenloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hosp
For personal use only. No other uses without permission.patient in each groupwas available to estimate theHR, which
may yield inaccurate estimates.
Therapeutic strategies often promote resolution of
infection and prevent further decline in the kidney allograft
function, but the damage from BKVN may not be reversed,
leading to chronic allograft dysfunction [1]. In fact, the
results demonstrated that even after strategies had been
implemented, a significant percentage of patients had
progressive allograft dysfunction. The potential for BKVN
to cause high rates of GL is well-documented [6]. We found
that 39.1% of patients (9 patients) had GL after the diag-
nosis of BKVN, a higher percentage than the 15% GL
previously described in Wadei et al [6], in which 55 kidney
transplant recipients, also with biopsy-proven BKVN, were
analyzed during 20  11 months of follow-up. Even when
patients had increased graft function after the diagnosis of
BKVN, more patients had partial recovery than total
recovery of the graft function.
This study had some limitations, such as a low number of
cases ofBKVNhistologically diagnosed, because surveillance
(“protocol”) biopsies were not performed and some patients
had contraindications to kidney allograft biopsy. At the time
of the biopsy, 16 patients hadGFR<30mL/min, and this late
diagnosis of BKVN could also be a limitation to the study
because these patients were already at a high risk for GL.
Chung et al [7] considered BK viremia to be a useful
predictor for BKVN and suggested that its regular moni-
toring was effective in preventing this pathology. The use of
this screening test could promote the early diagnosis of
BKVN and early initiation of the therapeutic strategies. The
BK viremia screening test was not performed in only 5 pa-
tients in this study because this test was not available in the
first years of the study.italar e Universitário de Coimbra from ClinicalKey.com by Elsevier on June 08, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
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DowCONCLUSIONS
We found that DGF and older age of the kidney transplant
recipients at the time of BKVN diagnosis were important
risk factors for GL. Patients with lower GFR at the time of
BKVN diagnosis were also at high risk for GL. Therefore,
early diagnosis of BKVN is essential to prevent GL.
REFERENCES
[1] Chon WJ, Aggarwal N, Kocherginsky M, et al. High-level
viruria as a screening tool for BK virus nephropathy in renal
transplant recipients. Kidney Res Clin Pract 2016;35:176e81.
[2] Hirsch HH, Randhawa P. BK polyomavirus in solid organ
transplantation. Am J Transplant 2013;13:179e88.nloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGAL-Centro Hosp
For personal use only. No other uses without permission.[3] Kidney Disease Improving Global Outcomes (KDIGO)
Transplant Working Group. KDIGO Clinical Practice Guidelines
for the Care of Kidney Transplant Recipients. Am J Transplant
2009;9:S44e6.
[4] Lanot A, Bouvier N, Chatelet V, et al. BK virus infections in
kidney transplantation. Nephrol Ther 2016;12:76e85.
[5] Nickeleit V, Mihatsch MJ. Polyomavirus nephropathy in
native kidneys and renal allografts: an update on as escalating
threat. Transplant Int 2006;19:960e73.
[6] Wadei HM, Rule AD, Lewin M, et al. Kidney transplant
function and histological clearance of virus following diagnosis
of polyomavirus-associated nephropathy. Am J Transplant
2006;6:1025e32.
[7] Chung BH, Hong YA, Kim HG, et al. Clinical usefulness of
BK virus plasma quantitative PCR to prevent BK virus associated
nephropathy. Transplant Int 2012;25:687e95.italar e Universitário de Coimbra from ClinicalKey.com by Elsevier on June 08, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
